Hospital Beatriz Angelo

Hospital Beatriz Angelo’s gastroenterology unit is conducting studies that aim to improve therapeutic options for chronic inflammatory bowel conditions, evaluating both novel biologics and oral small‑molecule agents.

• Moderately to severely active Crohn's Disease
• Ulcerative Colitis
• Inflammatory bowel disease

Across its 22 active trials, the site engages 20 investigators to assess efficacy, safety, and quality‑of‑life outcomes for patients with these digestive disorders.

Research at the hospital focuses on managing vasomotor symptoms that arise during adjuvant endocrine therapy for hormone‑receptor‑positive breast cancer, testing new oral compounds for symptom relief.

• Vasomotor symptoms (hot flashes)
• Hormone‑receptor‑positive breast cancer
• Adjuvant endocrine therapy

A dedicated trial evaluates the safety and effectiveness of elinzanetant compared with placebo in reducing these symptoms.

The site’s immunology research targets relapsing forms of multiple sclerosis and immune‑mediated kidney disorders, seeking to introduce next‑generation monoclonal antibodies and receptor inhibitors.

• Multiple Sclerosis (relapsing)
• Relapsing Multiple Sclerosis (RMS)
• Focal segmental glomerulosclerosis (FSGS)
• Immunoglobulin A Nephropathy (IgAN)

Ongoing studies assess ocrelizumab, ofatumumab, and remibrutinib for disease control and long‑term safety.

Oncology investigations at Hospital Beatriz Angelo include advanced breast cancer subtypes and EGFR‑mutated lung cancer, with a focus on targeted therapies and combination regimens that aim to extend survival.

• HER2‑positive breast cancer
• Hormone‑receptor‑positive/HER2‑negative breast cancer
• EGFR‑mutated locally advanced or metastatic non‑small cell lung cancer

Trials compare agents such as trastuzumab + pertuzumab, T‑DXd versus T‑DM1, and evaluate the added benefit of CDK4/6 inhibition with palbociclib.

Studies in the neurological portfolio aim to slow cognitive decline in early Alzheimer’s disease and to explore novel treatments for schizophrenia‑related cognitive impairment.

• Mild cognitive impairment (MCI) and early Alzheimer’s disease
• Schizophrenia with cognitive deficits

An ongoing trial evaluates oral semaglutide for its potential to preserve cognition over a two‑year period.

The department also investigates symptom‑directed therapies, including management of hot flashes and reduction of proteinuria in renal disease, to improve patient‑reported outcomes.

• Vasomotor symptoms related to endocrine therapy
• Proteinuria in IgA nephropathy
• Cognitive function decline

The sparsentan program tests its ability to lower proteinuria and preserve kidney function in IgAN and FSGS patients.

Psychiatric research at the site focuses on obsessive‑compulsive disorder and schizophrenia, evaluating innovative compounds designed to reduce symptom severity and improve daily functioning.

• Obsessive‑compulsive disorder (OCD)
• Schizophrenia

A phase‑III study examines the safety and efficacy of BP1.4979 as a potential new treatment for adults with OCD.